Peptide Research Hub
Educational reference
Educational reference only. Nothing on this site is medical advice. Many compounds described here are not FDA-approved, lack adequate human evidence, and may be illegal in your jurisdiction. Always consult a licensed clinician.

Growth Hormone Secretagogues

MK-677

Ibutamoren

Also known as: Ibutamoren L-163,191

Evidence: Moderate clinical Disclaimer: Elevated Not FDA-approved
Elevated-disclaimer compound. Not approved by the FDA. Evidence is limited to animal models or small human studies. Safety in humans has not been established.

Mechanism & research context

Non-peptide oral ghrelin receptor agonist studied in trials for sarcopenia and frailty. Development was not pursued to approval.

Safety flags

0 flags

No curator-recorded safety flags for this entry. Absence of recorded flags is not evidence of safety. Many peptides lack adequate human data.

Research papers

16 records

Citation links route to PubMed, Europe PMC, and PMC. Presence of a study is not endorsement. Records are refreshed from PubMed on a regular cadence; rows marked “Live search link” will resolve to a current PubMed search until a full citation has been ingested.

Clinical trials

9 records
  • Live search Live search

    Live ClinicalTrials.gov search: MK-677

    Condition: See live results

    Open on ClinicalTrials.gov ↗
  • NCT00074529 PHASE2 COMPLETED

    A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-0677 25 mg in Slowing the Progression of Alzheimer's Disease

    Condition: Alzheimer's Disease

    Sponsor: Merck Sharp & Dohme LLC

    Open on ClinicalTrials.gov ↗
  • NCT00116129 PHASE2 COMPLETED

    A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-0677 25 mg in the Treatment of Primary Fibromyalgia

    Condition: Fibromyalgia

    Sponsor: Bennett, Robert, M.D.

    Open on ClinicalTrials.gov ↗
  • NCT00128115 PHASE2 TERMINATED

    Proprietary Information - Exploratory (Non-Confirmatory) Trial

    Condition: Hip Fracture

    Sponsor: Merck Sharp & Dohme LLC

    Open on ClinicalTrials.gov ↗
  • NCT00395291 NA COMPLETED

    Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD Patients

    Condition: Chronic Kidney Disease; End Stage Renal Disease

    Sponsor: University of Virginia

    Open on ClinicalTrials.gov ↗
  • NCT00474279 PHASE1 COMPLETED

    Effects of an Oral GH Secretagogue (MK-677) on Body Composition and Functional Ability of Older Adults

    Condition: Aging

    Sponsor: University of Virginia

    Open on ClinicalTrials.gov ↗
  • NCT01343641 PHASE2 WITHDRAWN

    A Phase 2, Investigator-Initiated, Randomized, Double-Blind, Placebo-Controlled Study to Determine Growth Hormone Secretagogue MK-0677's Effect on Lean Body Mass in Chronic Kidney Disease Subjects With Stage 4 and Stage 5 Kidney Disease

    Condition: Chronic Kidney Disease; Kidney Disease

    Sponsor: University of Virginia

    Open on ClinicalTrials.gov ↗
  • NCT05364684 PHASE2 COMPLETED

    The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease: A Pilot Study

    Condition: NAFLD; Nonalcoholic Fatty Liver; NASH - Nonalcoholic Steatohepatitis

    Sponsor: Massachusetts General Hospital

    Open on ClinicalTrials.gov ↗
  • NCT06948214 PHASE3 RECRUITING

    A Multicenter, 12-Month, Randomized, Double Blind, Placebo-Controlled Phase 3 Efficacy and Safety Study of Daily Oral LUM-201 in Naïve-to-Treatment, Prepubertal Children With Growth Hormone Deficiency (GHD)

    Condition: Growth Hormone Deficiency (GHD)

    Sponsor: Lumos Pharma

    Open on ClinicalTrials.gov ↗

Doses reported in studies

0 records
This is not a dosing guide. Entries below are historical metadata transcribed verbatim from a cited clinical-trial protocol, published study, or FDA-approved label. They describe what was administered in a specific study population under medical supervision — they are not recommendations, not common-use guidance, and may not be safe or appropriate outside the cited context. Doses widely discussed in community/anecdotal sources are not shown here; see the safety policy for why.

No study-protocol dose records have been curated for MK-677 yet. Absence of records is not evidence of safety — many peptides lack adequate human-trial data in the first place.

Records here are populated from public sources only (ClinicalTrials.gov protocol summaries and FDA-approved labels) and must cite a verifiable source URL. They are not added from forum posts, vendor pages, anecdotal write-ups, or social media.

These entries describe what was studied. They do not tell you what to take, how to reconstitute anything, how to fill a capsule, how often to administer, or where to obtain a compound. If you are considering use of MK-677, those decisions belong with a licensed clinician working from the full label or trial record — not from this summary.

Why this page does not list a dose for self-use

The "Doses reported in studies" section above (when populated) describes what was administered in a cited study or label, under medical supervision, in a specific population. It is not a dosing guide for self-use. Separately, we do not publish anecdotal or community-reported dose ranges, administration methods, vial concentrations, or capsule masses for MK-677. Anecdotal figures for unapproved compounds are not harm-reduction data: they lack denominators for adverse events, cannot account for individual physiology or compound purity, and normalise unsupervised use. See the safety policy for the full reasoning.

If this compound has an FDA-approved label

If a label exists, the regulator-reviewed dosing and administration information is there — read it in the context of a prescriber's evaluation.

Questions worth bringing to a clinician

  • What is the evidence for this compound in someone with my history?
  • What are the realistic, regulator-reviewed alternatives?
  • What would you monitor, and what would make you stop?

If you have already taken a peptide and feel unwell: contact emergency services. In the United States, Poison Control is reachable 24/7 at 1-800-222-1222. Do not wait for a community thread.

Research peptides are not substitutes for medical care. If you are considering any peptide for health purposes, speak with a board-certified physician or endocrinologist first.